Encouraging Interim Results from ASC30 Study
Ascletis Pharma Inc. recently announced positive interim findings from the first two cohorts of their U.S. Phase Ib multiple ascending dose (MAD) study on ASC30, an oral medication aimed at treating obesity. This innovative treatment, available as a once-daily tablet, showed a remarkable 6.3% average body weight reduction in patients after a 28-day treatment in cohort 2. This cohort utilized weekly titrations of dosages, escalating from 2 mg to 40 mg.
Study Details and Findings
In cohort 1, which included a different set of dosages ranging from 2 mg to 20 mg, patients also demonstrated a significant average body weight reduction of 4.3%. In comparison, the placebo group showed only a 0.1% change in body weight following the same treatment duration. This places ASC30 in a favorable light compared to conventional treatments.
Understanding the Phase Ib MAD Study
The Phase Ib MAD study adhered to a randomized, double-blind, placebo-controlled design, engaging eight participants on ASC30 and two on placebo in each cohort. With shifting doses over seven days, patients in cohort 1 averaged a daily intake of 9.25 mg, while cohort 2's average was 18 mg. Such comprehensive data offers a clear understanding of ASC30’s potential effects on patients dealing with obesity.
Safety and Tolerability Profile
Patient safety remained a priority throughout the study. ASC30 exhibited a favorable safety profile with no reported serious adverse events (SAEs). Most gastrointestinal-related side effects were mild to moderate, and weekly dosage adjustments appeared to enhance tolerability. Impressively, cohort 1 saw no vomiting cases reported, showcasing ASC30's gentle approach to treatment.
Looking Ahead
At future medical conferences, Ascletis plans to unveil detailed results, further paving the way for ASC30 in obesity treatments. The unique qualifications of ASC30, as a first and only investigational small molecule GLP-1 receptor (GLP-1R) biased agonist available for daily oral use, mark a significant advancement in obesity therapy.
Innovative Dosing Options
Jinzi Jason Wu, the Founder, Chairman, and CEO of Ascletis, expressed enthusiasm about these results, stating that ASC30 could offer both an oral and a monthly subcutaneous injection for obese patients. This versatility could play a crucial role in patient adherence and the overall effectiveness of the treatment.
Overview of ASC30
ASC30 presents itself as a game-changer in the landscape of obesity treatment; this novel compound also possesses U.S. and global patent protections until 2044. Patients might have dual administration options available, lending credibility and utility to the compound as a groundbreaking solution for weight management.
About Ascletis Pharma Inc.
Ascletis operates with a commitment to innovative research and development in biotech, listed on the Hong Kong Stock Exchange (1672.HK). With a robust pipeline addressing therapeutic needs in metabolic and viral diseases, the company is positioned for future growth and success.
Frequently Asked Questions
What are the results of the ASC30 study?
The ASC30 study indicated significant body weight reductions of 4.3% and 6.3% in cohort 1 and cohort 2, respectively, over a 28-day treatment period.
How was the safety profile of ASC30 during the study?
ASC30 was well tolerated with no serious adverse events reported, and most gastrointestinal side effects were mild to moderate.
What are the dosing options for ASC30?
ASC30 can be taken as a once-daily oral tablet or administered intravenously once a month, enhancing treatment adherence.
Is ASC30 a new treatment option for obesity?
Yes, ASC30 is an investigational GLP-1R biased agonist designed specifically to aid in weight management.
When will detailed results of the study be presented?
Ascletis plans to share detailed results at upcoming medical conferences, further detailing the efficacy and safety of ASC30.
